BERKELEY, CA--(Marketwire - November 01, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the Oppenheimer 21st Annual Healthcare Conference on Tuesday, November 2, 2010 at 10:15 am EDT (7:15 am PDT) at the Waldorf Astoria Hotel in New York.
Michael Ostrach, Chief Business Officer of Dynavax, will provide a corporate overview presentation. To access the live webcast and the subsequent archived recording of the presentation, please log onto Dynavax’s website at http://investors.dynavax.com/newsevents.cfm.
About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company’s lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines.
Contact:
Shari Annes
Investor Relations
510-665-7211
Email Contact
